Example rapid review: Brexpiprazole for schizophrenia v2

Brexpiprazole for schizophrenia

Background: Brexpiprazole (proposed proprietary name “Rexulti”) is a new molecular entity atypical antipsychotic co-developed by Otsuka Pharmaceutical Co, Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck). The mechanism of action is unknown.

Methods: The FDA site was searched to locate relevant documents.  If these were not sufficient then EPARs from the European Medicines Agency were to be used.  Relevant data was extracted and used for a meta-analysis via RevMan. No journal articles were used.  The method is a pragmatic rapid systematic review.  The estimated time for the whole process was 60-90 minutes.

Primary efficacy endpoint: Mean reduction in PANSS total score at week 6.

Number of trials: 2. Study 230 = 657 patients, Study 231 = 623 patients.

Results:

additional graph

The above table is a summary of the 6 week results.  Below is the data presented as a meta-analysis for both doses:

brex

Over 6 weeks 2mg brexpiprazole produced a mean change in PANSS of 5.8, while the 4mg dose produced a change of 7.1.

Adverse events: In short-term, controlled trials, the percentage of subjects reporting >1 treatment-emergent adverse events (TEAEs) was similar in the brexpiprazole 2-4 mg/day, all brexpiprazole, and placebo groups (59.2%, 60.6%, and 61.1% respectively). Events reported by >5% of subjects the all brexpiprazole group included headache, akathisia, insomnia, and agitation. Only akathisia was reported by a higher percentage of subjects in the all brexpiprazole group than in the placebo group, and it did not reach the “most common” threshold of >5% and >2x placebo.

Conclusion: Compared with placebo, brexpiprazole appears to be effective in relation to the short-term (6 week) measure of reduction in PANSS.

References

NOTE: The review was based purely on the two FDA documents (with support and feedback from Erick Turner).  I was also helped by the statistician Mark Kelson (Research Fellow in Statistics, Cardiff University) who produced the meta-analyses. The inclusion of the two journal articles was purely for completeness.  The inclusion of the systematic review is for comparison purposes.
Advertisements

3 thoughts on “Example rapid review: Brexpiprazole for schizophrenia v2

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s